Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial

BACKGROUND: Immune checkpoint blockade with monoclonal antibodies targeting programmed death 1 (PD-1) and its ligand PD-L1 has played a major role in the rise of cancer immune therapy. We have identified naturally occurring self-reactive T cells specific to PD-L1 in both healthy donors and cancer pa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Front Immunol
Hauptverfasser: Jørgensen, Nicolai Grønne, Klausen, Uffe, Grauslund, Jacob Handlos, Helleberg, Carsten, Aagaard, Thomas Granum, Do, Trung Hieu, Ahmad, Shamaila Munir, Olsen, Lars Rønn, Klausen, Tobias Wirenfeldt, Breinholt, Marie Fredslund, Hansen, Morten, Martinenaite, Evelina, Met, Özcan, Svane, Inge Marie, Knudsen, Lene Meldgaard, Andersen, Mads Hald
Format: Artigo
Sprache:Inglês
Veröffentlicht: Frontiers Media S.A. 2020
Schlagworte:
Immunology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7680803/
https://ncbi.nlm.nih.gov/pubmed/33240282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.595035
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge